{"entity":{"id":"hutchmed","kind":"company","name":"Hutchmed","aka":["HUTCHMED (China)","Hutchison China MediTech","Chi-Med","和黄医药","Hutchison Medipharma","HUTCHMED"],"tldr":"Hutchmed discovered fruquintinib, the first Chinese cancer drug approved by the FDA for a common cancer, and savolitinib, its MET inhibitor partnered with AstraZeneca.","summary":"Shanghai discovery engine with three NMPA-approved originals: fruquintinib (colorectal 2018; FDA approval November 2023 after Takeda licensed ex-China rights for $400 million upfront), surufatinib (neuroendocrine tumours 2020) and savolitinib (MET exon 14 NSCLC 2021, with AstraZeneca). Also sovleplenib (Syk) and tazemetostat rights in China. Its FDA approval of fruquintinib in a global population (FRESCO-2) showed the route Chinese drugs must take: a multiregional confirmatory trial.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.hutch-med.com/"}],"tags":["china"],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["fruquintinib","savolitinib","surufatinib"],"companies":["takeda","astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06584032","nct05009836","nct06601504","nct06361888","nct03091192","nct03778229","nct07228247","nct07396584"],"people":["du-samantha"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Hong Kong / Shanghai","country":"CN","companyType":"biotech","website":"https://www.hutch-med.com/","ticker":"HCM / 13.HK","founded":2000,"investors":[],"funding":[]},"route":"/companies/hutchmed/","neighbours":{"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"drug":[{"id":"fruquintinib","kind":"drug","name":"Fruquintinib","route":"/drugs/fruquintinib/"},{"id":"hmpl-306","kind":"drug","name":"HMPL-306","route":"/drugs/hmpl-306/"},{"id":"hmpl-453","kind":"drug","name":"HMPL-453","route":"/drugs/hmpl-453/"},{"id":"hmpl-760","kind":"drug","name":"HMPL-760","route":"/drugs/hmpl-760/"},{"id":"iah0968","kind":"drug","name":"IAH0968","route":"/drugs/iah0968/"},{"id":"lb1410","kind":"drug","name":"LB1410","route":"/drugs/lb1410/"},{"id":"lb4330","kind":"drug","name":"LB4330","route":"/drugs/lb4330/"},{"id":"savolitinib","kind":"drug","name":"Savolitinib","route":"/drugs/savolitinib/"},{"id":"surufatinib","kind":"drug","name":"Surufatinib","route":"/drugs/surufatinib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"},{"id":"takeda","kind":"company","name":"Takeda","route":"/companies/takeda/"}],"trial":[{"id":"nct07228247","kind":"trial","name":"A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors","route":"/trials/nct07228247/"},{"id":"nct06361888","kind":"trial","name":"A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer","route":"/trials/nct06361888/"},{"id":"nct07409428","kind":"trial","name":"A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL","route":"/trials/nct07409428/"},{"id":"nct06387069","kind":"trial","name":"A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia","route":"/trials/nct06387069/"},{"id":"nct05009836","kind":"trial","name":"Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC","route":"/trials/nct05009836/"},{"id":"fresco","kind":"trial","name":"FRESCO","route":"/trials/fresco/"},{"id":"fresco-2","kind":"trial","name":"FRESCO-2","route":"/trials/fresco-2/"},{"id":"nct04353375","kind":"trial","name":"HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma","route":"/trials/nct04353375/"},{"id":"nct07396584","kind":"trial","name":"HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor","route":"/trials/nct07396584/"},{"id":"nct03778229","kind":"trial","name":"Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib","route":"/trials/nct03778229/"},{"id":"sanet","kind":"trial","name":"SANET-ep and SANET-p","route":"/trials/sanet/"},{"id":"nct03091192","kind":"trial","name":"Savolitinib vs. Sunitinib in MET-driven PRCC.","route":"/trials/nct03091192/"},{"id":"nct06584032","kind":"trial","name":"Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer","route":"/trials/nct06584032/"},{"id":"nct06601504","kind":"trial","name":"Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL","route":"/trials/nct06601504/"},{"id":"nct06504732","kind":"trial","name":"To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer","route":"/trials/nct06504732/"}],"person":[{"id":"du-samantha","kind":"person","name":"Samantha Du (Du Ying)","route":"/people/du-samantha/"},{"id":"su-weiguo","kind":"person","name":"Weiguo Su","route":"/people/su-weiguo/"}],"paper":[{"id":"paper-dasari-fresco-2-fruquintinib-lancet-2023","kind":"paper","name":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2)","route":"/key-papers/paper-dasari-fresco-2-fruquintinib-lancet-2023/"}]}}